PTEN and neoplasm: Our previous study has also shown the success of PEO-b-PBCL NP formulations of A83B4C63 as monotherapeutic in the selective inhibition of tumor growth in PTEN-deficient HCT116 tumor xenografts, due to synthetic lethality in this cancer model (33).